| Literature DB >> 32493953 |
Mehran Ghaderi1,2, Carlos Fernández Moro3,4, Soledad Pouso Elduayen4, Emilie Hultin3, Caroline Sophie Verbeke4,5, Mikael Björnstedt3,4, Joakim Dillner3,4.
Abstract
Ex-vivo tumor tissue culture systems are used as models to test specific anti-cancer drugs. Their main advantage is that they are closely comparable with the in vivo tumor in their host organism. We previously reported that precision-cut organotypic tissue slices of pancreatic ductal adenocarcinoma (PDAC) can be successfully cultured ex-vivo for at least 4 days. In order to study how culturing might affect transcription patterns, we now performed genome-wide transcriptome profiling of both baseline (0 h) and explanted tumors at daily intervals (24, 48 and 72 h) after start of culturing. The total-RNA from five samples of surgically resected human PDAC tumors at baseline and at different time points in culture was sequenced. Differential gene expression analysis of the whole transcriptome, testing 58,713 genes and over 206,000 transcripts, found that only a small number of genes showed significant changes in expression between baseline and cultured samples. The cultured tumor slices showed upregulation of a median of 12, 10 and 15 genes and downregulation of a median of 15, 12 and 25 genes at 24, 48 and 72 h in culture, respectively. One sample had morphologically increasing loss of tissue viability (range 0-18%). The vascular endothelial growth factor A (VEGFA) was significantly upregulated during the entire culture period in this case. Pathway over-representation analysis suggested that VEGFA together with the PTGS2 gene were upregulated at the same time as HIF-1-triggered cell apoptosis via NF-ĸB and the AP-1 activating factor was induced. Indeed, increased areas of apoptotic lesions were visible in this sample after 24 hours of culture. In conclusion, genome-wide transcriptome analysis supports that ex-vivo cultured tissue slices of PDAC may be a representative model of the original tumor. Transcriptome analysis was found to be a valuable complement to morphology for evaluation of ex-vivo cultures of PDAC.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32493953 PMCID: PMC7271237 DOI: 10.1038/s41598-020-65911-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Morphology-based analysis of tissue viability in the baseline (0 h) and cultured (24–2 h) tissue slices of PDAC samples OT5, OT9 and OT12. Non-viable tissue regions are indicated as red areas in the slice diagrams, their total percentages (with respect to the whole slice area) in red font and by red arrows in representative photomicrographs (hematoxylin-eosin staining, bar line: 100 μm).
Clinicopathological data and histological features of the slice cultures.
| Culture ID | Age | Gender | Grade of tumor differentiation | *Non-viable tissue (range %) | **Tumor cell outgrowth (range %) |
|---|---|---|---|---|---|
| OT1 | 68 | Male | Moderate | 0–3 | 7–15 |
| OT5 | 74 | Male | Well | 0–3 | 71–100 |
| OT9 | 62 | Male | Well | 0–18 | 55–76 |
| OT11 | 47 | Female | Moderate to poor | 0–6 | 23–47 |
| OT12 | 80 | Male | Moderate | 1–2 | 79–100 |
*Range % of non-viable tissue with respect to the entire tissue slice area, from time points 0 h to 72 h.
**Range % of tumor cell outgrowth with respect to the tissue slice perimeter, from time points 24 h to 72 h.
Total number of differentially expressed genes (p-value 0.05) in examined OT samples after ex-vivo harvest time from 24 to 72 hours.
| Sample | 24 h | 48 h | 72 h |
|---|---|---|---|
| OT1 | 19 (7 | 20 (7 | 21 (6 |
| OT5 | 36 (15 | 32 (26 | 47 (26 |
| OT9 | 52 (15 | 41 (10 | 56 (38 |
| OT11 | 0 (0 | 33 (23 | 40 (25 |
| OT12 | 23 (14 | 20 (12 | 15 (11 |
indicating upregulation and indicating downregulation of genes in compare to the baseline tumor.
Alphabetically ordered and white-spaced list of OT-sample transcripts (HGNC gene symbol used) that were over-represented in at least in one enriched pathway ConsensuspathDB-set.
| Sample | 24 h | 48 h | 72 h |
|---|---|---|---|
| OT1: | CHST2 | ADRA2C MMP14 | ADRA2C CRP |
| OT5: | ABCC8 | ABCC8 | ABCC8 |
| OT9: | ARC | ANK3 | BRCA1 |
| OT11: | No differentially expressed genes were found after 24 hours of culture. | A2M CPA1 CTSL PNLIP STC1 | A2M |
| OT12: | COL21A1 | None of the mapped entities (18 out of 20) were significantly over-represented in any pathway | CTSL |
Probability of the top 3 significantly suggested pathways according to the hypergeometric test in different databases.
| p-value | Pathway | Database | Mapped genes | ||
|---|---|---|---|---|---|
| OT1 | 24 h | 0.000122 | IL-17 signaling pathway - Homo sapiens (human) | KEGG | MAPK10; MUC5AC; CXCL8 |
| 24 h | 0.000182 | Overview of nanoparticle effects | Wikipathways | CXCL8; CRP | |
| 24 h | 0.000431 | nfkb activation by nontypeable hemophilus influenzae | BioCarta | CXCL8; MUC5AC | |
| 48 h | 0.000724 | Collagen degradation | Reactome | MMP14; CTSL | |
| 48 h | 0.000784 | Innate Immune System | Reactome | CRP; CTSL; TXNIP; OLFM4; SERPINA1; MUC5AC | |
| 48 h | 0.00154 | Xenobiotics metabolism | EHMN | CYP3A5; AKR1C1 | |
| 72 h | 0.000724 | Collagen degradation | Reactome | MMP14; CTSL | |
| 72 h | 0.00392 | Phenytoin (Antiarrhythmic) Action Pathway | SMPDB | HYOU1; TNNT2 | |
| 72 h | 0.00548 | Innate Immune System | Reactome | CRP; CTSL; TXNIP; OLFM4; MUC5AC | |
| OT5 | 24 h | 1.12e-05 | Validated targets of C-MYC transcriptional repression | PID | HMGCS2; NDRG1; NDRG2; SFRP1 |
| 24 h | 0.000266 | HIF-1-alpha transcription factor network | PID | ADM; PLIN2; NDRG1 | |
| 24 h | 0.000877 | Sympathetic Nerve Pathway (Neuroeffector Junction) | PharmGKB | ADM; ADRA2C | |
| 48 h | 1.92e-05 | Inflammatory Response Pathway | Wikipathways | IGHA2; THBS1; IGHM | |
| 48 h | 0.0028 | Cocaine addiction - Homo sapiens (human) | KEGG | PPP1R1B; CREB3L3 | |
| 48 h | 0.00326 | Peptide hormone metabolism | Reactome | INHBB; SLC30A8 | |
| 72 h | 0.00153 | Sympathetic Nerve Pathway (Neuroeffector Junction) | PharmGKB | ADM; ADRA2C | |
| 72 h | 0.00235 | Degradation of the extracellular matrix | Reactome | MMP11; CAPN13; CTSL | |
| 72 h | 0.0026 | Plasma lipoprotein remodeling | Reactome | CREB3L3; ALB | |
| OT9 | 24 h | 3.07e-06 | Photodynamic therapy-induced HIF-1 survival signaling | Wikipathways | PTGS2; IGFBP1; PMAIP1; VEGFA |
| 24 h | 7.54e-06 | Interleukin-4 and Interleukin-13 signaling | Wikipathways | PTGS2; OSM; VEGFA; F13A1; LIF | |
| 24 h | 3.54e-05 | HIF-1-alpha transcription factor network | PID | PLIN2; IGFBP1; HK2; VEGFA | |
| 48 h | 4.31e-05 | Photodynamic therapy-induced HIF-1 survival signaling | Wikipathways | PTGS2; PMAIP1; VEGFA | |
| 48 h | 0.000368 | Quercetin and Nf-kB- AP-1 Induced Cell Apoptosis | Wikipathways | PTGS2; VEGFA | |
| 48 h | 0.000661 | S1P1 pathway | PID | PTGS2; VEGFA | |
| 72 h | 2.37e-11 | Respiratory electron transport | Reactome | MT-CO2; MT-CO1; MT-CYB; … | |
| 72 h | 3.11e-11 | Electron Transport Chain (OXPHOS system in mitochondria) | Wikipathways | MT-ND6; MT-ND5; MT-ND4;… | |
| 72 h | 1.56e-10 | Respiratory electron transport, ATP synthesis by chemiosmotic coupling | Reactome | MT-CO2; MT-CO1; MT-CYB; … | |
| OT11 | 48 h | 2.48e-05 | AP-1 transcription factor network | PID | FOS; DUSP1; EGR1; PLAU |
| 48 h | 8.59e-05 | Pancreatic secretion - Homo sapiens (human) | KEGG | AMY2A; PNLIP; CPA1; CPA2 | |
| 48 h | 0.000126 | ErbB1 downstream signaling | PID | FOS; ZFP36; EGR1; DUSP1 | |
| 72 h | 1.33e-05 | Post-translational protein phosphorylation | Reactome | SPARCL1; CP; F5; SERPINA1; IGFBP1 | |
| 72 h | 2.69e-05 | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | Reactome | SPARCL1; CP; F5; SERPINA1; IGFBP1 | |
| 72 h | 0.000316 | IL6-mediated signaling events | PID | CRP; FOS; A2M | |
| OT12 | 24 h | 4.01e-06 | Collagen formation | Reactome | LAMC2; COL7A1; CTSL; COL21A1 |
| 24 h | 2.56e-05 | Assembly of collagen fibrils and other multimeric structures | Reactome | LAMC2; CTSL; COL7A1 | |
| 24 h | 2.97e-05 | Anchoring fibril formation | Reactome | COL7A1; LAMC2 | |
| 72 h | 0.000147 | Collagen degradation | Reactome | MMP14; CTSL | |
| 72 h | 0.00132 | Degradation of the extracellular matrix | Reactome | MMP14; CTSL | |
| 72 h | 0.0065 | VEGFA-VEGFR2 Signaling Pathway | Wikipathways | MMP14; TXNIP |